Complement receptor 1 (CR1) plays an important role in the development of sporadic Alzheimer’s disease (SAD) in Caucasians. However, the influence of CR1 (rs6656401A/G and rs3818361T/C) genetic polymorphisms on the risk of SAD remains controversial. A meta-analysis of 18 case-control studies was performed to derive a more precise association of CR1 (rs6656401A/G or rs3818361T/C) genetic polymorphism with the risk of SAD in Caucasians. A statistical difference was found in the dominant model (OR:1.23, 95%CI:1.16-1.30, p=0.00), recessive model (OR:1.28, 95%CI:1.05-1.56, p=0.02), homozygote comparison (OR:1.36, 95%CI:1.12-1.66, p=0.002) or heterozygote comparison (AG versus GG) (OR:1.21, 95%CI:1.15-1.29, p=0.00) of CR1 rs6656401A/G. For CR1 rs3818361T/C, a statistical difference was observed in the dominant model (OR:1.21, 95%CI:1.13-1.31, p=0.00), recessive model (OR:1.28, 95%CI:1.07-1.53, p=0.006), homozygote comparison (OR:1.35, 95%CI:1.13-1.62, p=0.001) or heterozygote comparison (TC versus CC) (OR:1.20, 95%CI:1.11-1.29, p=0.00). In summary, despite some limitations, the present meta-analysis indicated that rs6656401A/G or rs3818361T/C polymorphism was related to SAD risk. Moreover, A carrier of rs6656401A/G or T carrier of rs3818361T/C in CR1 genetic polymorphism might be an increased factor for SAD in Caucasians.

This content is only available as a PDF.
This is an Accepted Manuscript; not the final Version of Record. You are encouraged to use the final Version of Record that, when published, will replace this manuscript and be freely available under a Creative Commons licence.